A Phase III Long Term Study of K-877 Extended Release Tablet

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

Also called NCT04716595

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04716595
Other papers using this trial's data
  • Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study Journal of atherosclerosis and thrombosis, 2025-08-01 DOI, PubMed 39924184, PMC12328711 In the PMC Open Access subset under CC BY-NC-SA.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04716595. Randomized; no masking; primary purpose treatment. Start 2021-02-01 (actual); primary completion 2022-06-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Long Term Study of K-877 Extended Release Tablet
Condition
Dyslipidemias
Intervention (Drug)
K-877 ER 0.2 mg/day morning administration (once daily)
Intervention (Drug)
K-877 ER 0.2 mg/day evening administration (once daily)
Lead sponsor
Kowa Company, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04716595
Content hash
e6a26ba72ef14c294bd5383fd1bd8facaa919f789c8d3bd9b2357d78733551da